IGF-1 LR3: Benefits, Dosage & Side Effects
IGF-1 LR3 Long-acting IGF-1 for direct muscle growth What is IGF-1 LR3? IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is a synthetic, modified form of human IGF-1. The "LR3" refers to two key modifications: an arginine substitution at position 3 and a 13-
IGF-1 LR3
Long-acting IGF-1 for direct muscle growth
What is IGF-1 LR3?
IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is a synthetic, modified form of human IGF-1. The "LR3" refers to two key modifications: an arginine substitution at position 3 and a 13-amino-acid N-terminal extension peptide. These changes reduce binding to IGF-binding proteins (IGFBPs), which normally sequester and deactivate circulating IGF-1. The result is a molecule that stays active in the bloodstream for 20-30 hours instead of the 10-15 minutes of native IGF-1.
Why does this matter? IGF-1 is the primary downstream mediator of growth hormone's anabolic effects. When GH stimulates the liver and other tissues, they produce IGF-1, which then drives muscle protein synthesis, satellite cell proliferation, and cellular growth. By injecting IGF-1 LR3 directly, you skip the GH step entirely and deliver the growth signal straight to the tissues. This makes it one of the most directly anabolic peptides available.
IGF-1 LR3 occupies a different niche than GH secretagogues like Ipamorelin, CJC-1295, or MK-677. Those peptides stimulate your pituitary to release more GH, which then raises IGF-1 indirectly. IGF-1 LR3 bypasses the entire hypothalamic-pituitary axis and acts directly on IGF-1 receptors in muscle, bone, and connective tissue. This is both its strength (direct, potent anabolic signaling) and its risk (no physiological feedback to regulate levels).
Because of its potency and the lack of regulatory feedback, IGF-1 LR3 is classified as an advanced peptide. It requires careful dosing, attention to blood glucose levels, and an understanding of its interactions with insulin signaling. For a detailed guide on protocols, see our IGF-1 LR3 dosage protocol blog article. For reconstitution and dosing math, use the Peptide Reconstitution Calculator.
How IGF-1 LR3 Works
IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor found on nearly every cell type. In muscle tissue, IGF-1R activation triggers two major intracellular pathways:
PI3K/Akt/mTOR Pathway: This is the primary anabolic signaling cascade. Akt activation phosphorylates mTOR (mechanistic target of rapamycin), which upregulates protein synthesis by activating p70S6K and 4E-BP1. This is the same pathway activated by resistance training and amino acid availability, which is why IGF-1 LR3 synergizes with both.
MAPK/ERK Pathway: This pathway drives cell proliferation and differentiation. In the context of muscle, it promotes satellite cell activation and proliferation. Satellite cells are muscle stem cells that fuse with existing muscle fibers to support repair and growth (hypertrophy) or, under sufficient stimulus, can form entirely new muscle fibers (hyperplasia).
The LR3 modification is critical to the pharmacology. Native IGF-1 has a half-life of about 10-15 minutes because it is rapidly bound by six different IGFBPs that sequester it in inactive complexes. The arginine substitution at position 3 and the N-terminal extension reduce IGFBP binding by over 100-fold. This means IGF-1 LR3 circulates in its free, active form for much longer, with a functional half-life of 20-30 hours.
IGF-1 LR3 also has cross-reactivity with the insulin receptor, though at much lower affinity than insulin itself. At high doses, this can cause hypoglycemia, which is the most acute safety concern with this peptide. The insulin receptor cross-reactivity also means IGF-1 LR3 promotes glucose uptake into muscle cells and enhances nutrient partitioning.
Benefits of IGF-1 LR3
Direct Muscle Hypertrophy IGF-1 LR3 activates mTOR signaling directly in muscle cells, driving protein synthesis independently of GH. This makes it one of the most directly anabolic peptides available. Users report noticeable increases in muscle fullness and density within 2-4 weeks at standard doses. The effect stacks additively with resistance training and adequate protein intake.
Muscle Hyperplasia Unlike most anabolic compounds that only increase the size of existing muscle fibers (hypertrophy), IGF-1 signaling can promote the formation of new muscle fibers (hyperplasia) through satellite cell activation and differentiation. This is one of the most unique and sought-after properties of IGF-1 LR3. The extent to which hyperplasia occurs in humans at typical doses is debated, but the mechanism is well established in cell culture and animal studies.
Satellite Cell Activation Satellite cells are the body's reserve of muscle stem cells. They normally sit dormant until activated by muscle damage or growth signals. IGF-1 LR3 is one of the most potent activators of satellite cell proliferation and differentiation. This translates to improved muscle repair after training and a larger pool of myonuclei available for long-term growth.
Nutrient Partitioning IGF-1 LR3 enhances the preferential shuttling of nutrients (glucose, amino acids) into muscle tissue rather than fat stores. This partitioning effect is partly mediated through insulin receptor cross-reactivity and partly through direct metabolic effects in muscle cells. Users often notice they can eat more without gaining fat during an IGF-1 LR3 cycle.
Connective Tissue Support IGF-1 receptors are present on chondrocytes (cartilage cells), osteoblasts (bone cells), and fibroblasts (connective tissue cells). IGF-1 LR3 supports collagen synthesis and connective tissue repair, which is valuable for athletes pushing heavy training loads. This pairs well with healing peptides like BPC-157 for injury recovery.
Side Effects & Safety
Common Side Effects - Hypoglycemia (low blood sugar), especially at higher doses or when combined with insulin. Symptoms include shakiness, sweating, dizziness, and confusion. - Mild water retention - Intestinal growth (gut distension) with prolonged high-dose use - Injection site soreness or lumps - Lethargy and fatigue, especially post-injection
Less Common Side Effects - Joint pain from rapid tissue growth - Jaw or extremity growth with chronic high-dose use (acromegaly-like effects) - Headache - Transient vision changes
Contraindications and Cautions - IGF-1 LR3 is strictly contraindicated in anyone with active or suspected cancer. IGF-1 receptor activation is a major driver of tumor cell proliferation, and elevated IGF-1 levels are epidemiologically linked to increased cancer risk. - Diabetics and pre-diabetics must exercise extreme caution due to hypoglycemia risk. - Do not combine with exogenous insulin unless you have extensive experience and medical supervision. The combination carries a real risk of severe, life-threatening hypoglycemia. - Not recommended for anyone under 25, as IGF-1 signaling can affect growth plate closure and organ development. - Pregnant or breastfeeding women must not use IGF-1 LR3. - This peptide is prohibited by WADA and is tested for in competitive sports. - Long-term safety data in healthy humans is practically nonexistent. Keep cycles short and doses moderate.
IGF-1 LR3 Dosage Protocols
Conservative Protocol
20 mcg/day
Once daily, post-workout on training days, morning on rest days
4 weeks on, 4 weeks off
Standard Protocol
40-50 mcg/day
Once daily, post-workout preferred
4-6 weeks on, 4-6 weeks off
Advanced Stack Protocol
30-50 mcg/day IGF-1 LR3 + GH secretagogue
IGF-1 LR3 once daily post-workout; GH peptides 2-3x daily
4-6 weeks IGF-1 LR3, GH peptides can continue longer
Conservative Protocol: The starting dose for first-time IGF-1 LR3 users. Inject subcutaneously. Have a carbohydrate source available in case of hypoglycemia symptoms. Monitor blood glucose if possible. Keep cycles short until you understand your response.
Standard Protocol: The most common dose in experienced user protocols. Some users split into bilateral intramuscular injections into the trained muscle groups for localized effects, though systemic delivery via subcutaneous injection also works. Do not exceed 50 mcg/day without significant experience.
Advanced Stack Protocol: Combines direct IGF-1 signaling with elevated GH from secretagogues like Ipamorelin + CJC-1295. The GH secretagogues provide systemic GH benefits (fat loss, sleep, recovery) while IGF-1 LR3 drives direct anabolism. Time IGF-1 LR3 away from GH peptides to avoid overlapping insulin suppression effects.
These are general guidelines for research purposes. Always consult a healthcare professional before use.
Is IGF-1 LR3 Right for You?
Take our quiz to get a personalized recommendation based on your goals and profile.
Stacking IGF-1 LR3
Add natural GH elevation to direct IGF-1 signaling
IGF-1 LR3 at 30-50 mcg post-workout + Ipamorelin at 200-300 mcg before bed. Ipamorelin provides the GH pulse for fat loss, sleep, and recovery, while IGF-1 LR3 delivers direct anabolic signaling to muscle. Separate the two by several hours. Run IGF-1 LR3 for 4-6 weeks; Ipamorelin can continue for 12-16 weeks.
Sustained GH elevation combined with direct IGF-1 action
IGF-1 LR3 at 30-50 mcg daily + CJC-1295 (with DAC) at 2 mg per week. The CJC-1295 provides a sustained GH baseline throughout the week, while IGF-1 LR3 adds direct tissue-level anabolic signaling. This is a potent combination. Monitor blood glucose and IGF-1 blood levels if possible.
Convenient oral GH support alongside injectable IGF-1 LR3
IGF-1 LR3 at 20-40 mcg daily + MK-677 at 12.5-25 mg orally before bed. MK-677 provides 24/7 GH elevation from a single oral dose, reducing the injection burden. Watch for compounding effects on insulin sensitivity and water retention. Check the [Peptide Interaction Checker](/tools/peptide-interaction-checker) before starting.
Frequently Asked Questions
Native IGF-1 has a half-life of only 10-15 minutes because binding proteins rapidly sequester it. IGF-1 LR3 has two structural modifications that reduce binding protein affinity by over 100-fold, extending the active half-life to 20-30 hours. This means it stays active in the bloodstream much longer and produces more sustained anabolic signaling per dose.
Yes, this is the most acute safety concern. IGF-1 LR3 has cross-reactivity with the insulin receptor, meaning it can lower blood glucose, especially at higher doses (50+ mcg). Always have fast-acting carbs available when injecting. Symptoms include shakiness, sweating, dizziness, and confusion. If you experience these, consume 15-20g of sugar immediately. Never combine IGF-1 LR3 with insulin without medical supervision.
Both, in theory. IGF-1 is one of the few compounds that activates satellite cells and promotes their differentiation into new myofibers, which is the mechanism for hyperplasia. This is well documented in cell culture and animal models. Whether typical human doses produce meaningful hyperplasia is debated, but the satellite cell activation and enhanced repair capacity are well supported.
They serve different purposes and are not directly comparable. GH secretagogues (like Ipamorelin and CJC-1295) raise GH, which has broad systemic effects: fat loss, sleep improvement, recovery, skin quality, and yes, some muscle growth via endogenous IGF-1 production. IGF-1 LR3 bypasses GH entirely and delivers direct anabolic signaling to tissues. For pure muscle growth, IGF-1 LR3 is more targeted. For overall health optimization, GH secretagogues are more versatile.
Several reasons. First, sustained high IGF-1 levels are associated with increased cancer risk in epidemiological studies. Second, chronic IGF-1 elevation can cause organ and tissue overgrowth (intestinal growth, joint thickening). Third, prolonged insulin receptor cross-activation can worsen insulin sensitivity over time. Cycling 4-6 weeks on and off limits these risks while still providing meaningful anabolic benefits.
This is a common practice, but the evidence that site-specific injection produces localized muscle growth is limited. Given the 20-30 hour half-life, IGF-1 LR3 circulates systemically regardless of injection site. Subcutaneous injection in the abdominal area is simpler and equally effective for systemic benefits. Some advanced users still prefer intramuscular injection for theoretical local concentration advantages.
Yes, and it can be particularly effective for preserving muscle during a cut. The direct mTOR activation and enhanced nutrient partitioning help muscle cells hold onto protein even in a catabolic environment. However, be cautious about hypoglycemia risk, which is heightened during caloric restriction. Start with a lower dose (20 mcg) and monitor your blood sugar response carefully.
Not Sure Which Peptide Protocol Is Right for You?
Take our 2-minute quiz for a personalized recommendation based on your goals and health profile.